1855 related articles for article (PubMed ID: 22461641)
21. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
22. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
Rodić N; Anders RA; Eshleman JR; Lin MT; Xu H; Kim JH; Beierl K; Chen S; Luber BS; Wang H; Topalian SL; Pardoll DM; Taube JM
Cancer Immunol Res; 2015 Feb; 3(2):110-5. PubMed ID: 25370533
[TBL] [Abstract][Full Text] [Related]
24. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
Chapon M; Randriamampita C; Maubec E; Badoual C; Fouquet S; Wang SF; Marinho E; Farhi D; Garcette M; Jacobelli S; Rouquette A; Carlotti A; Girod A; Prévost-Blondel A; Trautmann A; Avril MF; Bercovici N
J Invest Dermatol; 2011 Jun; 131(6):1300-7. PubMed ID: 21346771
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
26. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
27. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
28. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
30. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
Ghebeh H; Mohammed S; Al-Omair A; Qattan A; Lehe C; Al-Qudaihi G; Elkum N; Alshabanah M; Bin Amer S; Tulbah A; Ajarim D; Al-Tweigeri T; Dermime S
Neoplasia; 2006 Mar; 8(3):190-8. PubMed ID: 16611412
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.
Nakanishi J; Wada Y; Matsumoto K; Azuma M; Kikuchi K; Ueda S
Cancer Immunol Immunother; 2007 Aug; 56(8):1173-82. PubMed ID: 17186290
[TBL] [Abstract][Full Text] [Related]
32. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
[TBL] [Abstract][Full Text] [Related]
34. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
Wang S; Liechty B; Patel S; Weber JS; Hollmann TJ; Snuderl M; Karajannis MA
J Neurooncol; 2018 May; 138(1):183-190. PubMed ID: 29427150
[TBL] [Abstract][Full Text] [Related]
35. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
36. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
[TBL] [Abstract][Full Text] [Related]
37. ROCK1 and ROCK2 Are Down-regulated in Aggressive and Advanced Skin Melanomas - A Clinicopathological Perspective.
Kaczorowski M; Biecek P; Donizy P; Pieniążek M; Matkowski R; Hałoń A
Anticancer Res; 2020 Apr; 40(4):1931-1942. PubMed ID: 32234882
[TBL] [Abstract][Full Text] [Related]
38. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
Pelekanou V; Barlow WE; Nahleh ZA; Wasserman B; Lo YC; von Wahlde MK; Hayes D; Hortobagyi GN; Gralow J; Tripathy D; Porter P; Szekely B; Hatzis C; Rimm DL; Pusztai L
Mol Cancer Ther; 2018 Jun; 17(6):1324-1331. PubMed ID: 29588392
[TBL] [Abstract][Full Text] [Related]
39. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response.
Quandt D; Fiedler E; Boettcher D; Marsch WCh; Seliger B
Clin Cancer Res; 2011 May; 17(10):3100-11. PubMed ID: 21378130
[TBL] [Abstract][Full Text] [Related]
40. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.
Liu J; Hamrouni A; Wolowiec D; Coiteux V; Kuliczkowski K; Hetuin D; Saudemont A; Quesnel B
Blood; 2007 Jul; 110(1):296-304. PubMed ID: 17363736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
